Market expansion Chiesi Deutschland operates as part of a global, privately managed pharma group with a footprint in ~100 countries and 31 subsidiaries. This presents cross-border collaboration, product placement, and distribution opportunities for compatible respiratory, neonatology, transplant, and rare disease therapies across European and global markets.

Strategic acquisitions Recent M&A activity by the parent group (Amryt Pharma acquisition and biotech investments) signals a growth-and-innovation strategy. This creates potential channels for partnership on pipeline assets, co-development deals, or regional license arrangements to accelerate market entry.

Innovation platforms Launch of an innovation platform and Biotech Center of Excellence in Parma indicates a focus on next-generation therapies and collaboration with biotech entities. Explore opportunities for joint research, early access programs, or technology licensing to enhance product portfolios and accelerate timelines.

Regulatory and compliance Chiesi maintains formal compliance and certification standings (ISO 37001, SAP SuccessFactors, Top Employer, Great Place to Work). This reduces risk in potential partnerships and supports scalable joint ventures, outsourcing, and supplier relationships with a strong governance framework.

Market positioning With a revenue range in the mid-tier and a focus on respiratory, neonatology, transplant, and rare diseases, there is room to position supplementary products, complementary therapies, or dermal delivery/adjunct therapies within German and European health systems, targeting hospitals, clinics, and specialty centers.